SMMT Earnings Preview

FDA accepts ivonescimab BLA; Phase III trials expanding

BLA acceptance validates ivonescimab's safety and manufacturing quality ahead of potential approval; the drug's efficacy now rests entirely on Phase III outcomes. Doubling net losses year-over-year signals accelerating spend on trial expansion, which is typical pre-commercialization but compresses the runway. Cash position is adequate for 2-3 years of operations at current burn rates, but approval timing and trial readouts are existential.

Watch: Phase III data readouts for non-small cell lung cancer and colorectal cancer trials — these will determine whether ivonescimab can carve a niche in an increasingly crowded checkpoint inhibitor market. Any expansion of the GSK partnership terms or new clinical combinations would signal confidence in the molecule's potential beyond its current indications.